HLA Antibody Incompatible Renal Transplantation: Long-term Outcomes Similar to Deceased Donor Transplantation.
Author
Krishnan, NithyaAbimbola, Aisha
Machan, Nandhini
Daga, Sunil
Gopalakrishnan, Kishore
Lam, ForTai
Tan, LamChin
Kashi, Habib
Zehnder, Daniel
Collins, Claire
Curtis, Rebecca
Higgins, Robert
Khovanova, Natasha
Briggs, David
imray, chris
Publication date
2021-07-19
Metadata
Show full item recordAbstract
The overall patient survival was 95%, 90%, and 81%; and graft survival was 95%, 85%, and 70% at 1, 5, and 10 y, respectively. This was similar to the first-time deceased donor transplant cohort. The graft survival for pretreatment cytotoxic-dependent crossmatch (CDC) positive crossmatch group was significantly low at 83%, 64%, and 40% at 1, 5, and 10 y, respectively, compared with other groups (Bead/CDC, P = 0.007; CDC/Flow, P = 0.001; and microbead assay/flow cytometry crossmatch, P = 0.837), although those with a low CDC titer (<1 in 2) have comparable outcomes to the CDC negative group. Female patients in general fared worse in both patient and graft survival outcomes in each of the 3 groups based on pretreatment crossmatch, although this did not reach statistical significance. Antibody-mediated rejection was the most frequent type of rejection with significant decline in graft survival by 10 y when compared with no rejection (P < 0.001). Rejection that occurred or continued to occur after the first 2 wk of transplantation caused a significant reduction in graft survivals (P < 0.001), whereas good outcomes were seen in those with a single early rejection episode.Citation
Transplant Direct . 2021 Jul 19;7(8):e732Type
ArticleAdditional Links
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291351/PMID
34291154Journal
Transplantation DirectPublisher
Wolters Kluwerae974a485f413a2113503eed53cd6c53
10.1097/TXD.0000000000001183